Skip to main content
Equibles
PDSB logo

PDSB · PDS Biotechnology Corp · Metrics

Track PDSB — free

Use PDSB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PDSB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.30 +0.01 (+3.99%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As a result of these uncertainties, the Company has concluded that substantial doubt exists about the Company's ability to continue as a going concern for a period of at least 12 months from the date of the issuance of these unaudited Condensed Consolidated Financial Statements.”
View the 10-Q filed Aug 13, 2026
Market Cap
$16.40M
Shares
55.97M

PDSB metrics

49 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.29
Market cap
$16.40M

Price action

20 metrics
Price change (1W)
+47.1%
Price change (30D)
-59.0%
Price change (3M)
-70.9%
Price change (6M)
-56.3%
Price change (YTD)
-61.0%
Price change (1Y)
-74.4%
Trailing year
Price change (5Y)
-98.0%
52-week high
$1.43
52-week low
$0.20
Change from 52-week high
-79.0%
Change from 52-week low
+49.5%
Annualized volatility
122.6%
Annualized volatility (3M)
158.5%
Beta
2.9
RSI (14D)
42.3
Price vs SMA 50
-44.8%
Price vs SMA 200
-62.9%
Avg volume (3M)
9.06M
Relative volume
54.2
Average dollar volume
$2.81M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
55.97M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-205.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-05-13

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$27.83M
Net income (TTM)
−$33.67M
Trailing 12 months
Diluted EPS (TTM)
$-0.63
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.17

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+21.3%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-382.3%
Debt / equity
—
Current ratio
0.6
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.6
Interest coverage
-4.2
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$5.60M
Total assets
$8.81M
Total debt
$15.00M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$16.78M
Capital expenditures (TTM)
—
R&D (TTM)
$15.70M
SG&A (TTM)
—
Stock compensation (TTM)
$4.69M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
53
13F filer change QoQ
+10
Institutional ownership
14.4%

Short interest

3 metrics
Short interest
3.4%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
63 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1472091 CUSIP 70465T107 13F (30d) 38 filings 38 filers Visit website Investor relations